the protocol described here efficiently directs human pluripotent stem cells (hpscs) to functional cardiomyocytes in a completely defined, growth factor-and serum-free system by temporal modulation of regulators of canonical Wnt signaling. appropriate temporal application of a glycogen synthase kinase 3 (GsK3) inhibitor combined with the expression of b-catenin shrna or a chemical Wnt inhibitor is sufficient to produce a high yield (0.8-1.3 million cardiomyocytes per cm 2 ) of virtually pure (80-98%) functional cardiomyocytes in 14 d from multiple hpsc lines without cell sorting or selection. Qualitative (immunostaining) and quantitative (flow cytometry) characterization of differentiated cells is described to assess the expression of cardiac transcription factors and myofilament proteins. Flow cytometry of Brdu incorporation or Ki67 expression in conjunction with cardiac sarcomere myosin protein expression can be used to determine the proliferative capacity of hpsc-derived cardiomyocytes. Functional human cardiomyocytes differentiated via these protocols may constitute a potential cell source for heart disease modeling, drug screening and cell-based therapeutic applications.
IntroDuctIon
Directed differentiation of specific lineages from hPSCs, including human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), is the first critical step toward constructing development or disease models, drug screening tools or cellular therapies from hPSCs. Because postnatal cardiomyocytes have little or no regenerative capacity, very limited supplies of human cardiomyocytes are available at present. hPSCs could potentially provide an unlimited supply of cardiomyocytes from a single clonal source.
Methods to differentiate hPSCs into cardiomyocytes
Initial efforts to differentiate hESCs into cardiomyocytes employed embryoid bodies (EBs) in medium containing fetal calf serum, but this method is inefficient, with the culture typically composed of less than 1% cardiomyocytes, and provides variable results in different hPSC lines 1 . Mouse End-2 (visceral endoderm-like) cell-conditioned medium has been shown to enhance cardiac differentiation in EBs 2 . The appropriate temporal addition of growth factors important in cardiovascular development, including fibroblast growth factor 2 (FGF2), transforming growth factor β (TGF-β) superfamily growth factors activin A and BMP4, vascular endothelial growth factor and the Wnt inhibitor DKK-1, can enhance cardiomyocyte differentiation in EBs 3 . Monitoring the onset of KDR/c-KIT 3 or FLK1/PDGFR-α (ref. 4 ) expression during the differentiation protocol enables the presentation of these differentiation factors at the appropriate developmental stage, resulting in relatively consistent cardiomyocyte yields in multiple hPSC lines 4 . In previous work, we reported that undifferentiated hPSC expansion conditions affect cardiomyocyte yield [5] [6] [7] [8] . Pretreatment of hPSCs with a GSK3 inhibitor before forming EBs greatly enhanced cardiac differentiation using serum-based EB differentiation 7 .
As an alternative to hPSC differentiation to cardiomyocytes via EBs, a monolayer-based directed differentiation platform was developed. This protocol sequentially exposes the hPSCs to activin A and BMP4 in defined RPMI/B-27 medium, and has been reported to be much more efficient than serum-based EB differentiation, generating greater than 30% cardiomyocytes in the H7 hESC line 9, 10 . However, the efficiency of the activin A and BMP4 monolayerdirected differentiation protocol is highly variable between cell lines and experimental repeats within the same line 11 . We modified this protocol in two ways, optimizing GSK3 inhibitor pretreatment concentration at the undifferentiated hPSC expansion stage and insulin concentration during the first 5 d of differentiation. We found that insulin, present in B-27 supplement, greatly inhibits cardiomyocyte yield during the first 5 d of differentiation, which is consistent with previous reports that insulin inhibits cardiac differentiation of hPSCs 12, 13 . We therefore used B-27 supplement lacking insulin in the cardiomyocyte differentiation medium. We also found that GSK3 inhibitor pretreatment of undifferentiated hPSCs is crucial for robust cardiac differentiation. We obtained less than 1% cardiomyocytes using the original RPMI/B-27 monolayer-directed differentiation protocol in several hPSC lines (H9, H13, H14, 19-9-11, 6-9-9 and IMR90C4) that we tested in several experimental repeats (n > 5). However, the use of B-27 supplement without insulin and GSK3 inhibitor pretreatment in the activin A and BMP4 monolayer-directed differentiation protocol generated 30-90% cardiomyocytes across these hPSC lines 14 . Neither B-27 lacking insulin nor GSK3 inhibitor pretreatment alone was sufficient for efficient cardiomyocyte differentiation in this protocol.
Consistent with our findings that hPSC pretreatment with a GSK3 inhibitor greatly improved cardiac differentiation of hPSCs, Wnt signaling has also been shown to have a biphasic effect on cardiac development in zebrafish, mouse embryos and mouse embryonic stem cells 15, 16 , with early Wnt signaling enhancing and later Wnt signaling repressing heart development. Because of the important temporal roles of Wnt/β-catenin on cardiac differentiation, we assessed whether modulation of Wnt/β-catenin signaling, Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/b-catenin signaling under fully defined conditions in the absence of exogenous activin A and BMP4, was sufficient to efficiently produce cardiomyocytes from hPSCs. We found that sequential activation of canonical Wnt signaling by GSK3 inhibitor treatment and inhibition of Wnt signaling by inducible expression of β-catenin shRNA is sufficient to drive multiple hPSC lines to cardiomyocytes 7 . Small-molecule inhibitors of Wnt ligand production (IWPs) also induced cardiac differentiation as effectively as β-catenin shRNA expression 7 . Other inhibitors of Wnt signaling, including IWR-1-endo 17 and XAV939 (ref. 18) , have also been show to promote cardiac differentiation of pluripotent stem cells.
Experimental design
Choice of cardiomyocyte differentiation method. Here we provide three approaches for efficient generation of functional human cardiomyocytes from hPSCs, the first approach using TGF-β superfamily growth factors ( Step 12C, GiAB) and the others using smallmolecule activators of canonical Wnt signaling followed by shRNA of β-catenin expression (Step 12A, GiSB) or small-molecule inhibitors of Wnt signaling (Step 12B, GiWi) in a growth factor-free system.
Step 12C relies on treatment of undifferentiated hPSCs with a GSK3 inhibitor in mTeSR1; this is followed by treatment with activin A and BMP4 in RPMI/B-27 supplement without insulin. The smallmolecule options (Steps 12A and 12B) use sequential treatment of GSK3 inhibitors and Wnt signaling inhibitors (or inducible expression of β-catenin shRNA) to stimulate cardiogenesis. Compared with growth factor-induced cardiomyocyte differentiation, the small-molecule approaches (Steps 12A and 12B) provide more robust cardiac differentiation, producing 80-98% cardiomyocytes from six hPSC lines (Table 1) . Although inducible expression of β-catenin shRNA provides specific and facile temporal regulation of canonical Wnt signaling, this method (Step 12A) requires genetic modification of the hPSC line.
Step 12B, which uses Wnt signaling inhibitors instead of β-catenin shRNA, does not require genetic modification and is applicable to any existing hPSC line. All three approaches can be performed under fully defined conditions with defined medium (RPMI/B-27 without insulin) and defined substrates (Synthemax plates). The protocol will enable efficient production of human cardiomyocytes for development and disease research, drug screening and testing and advancing cardiac cellular therapies.
Quality of hPSCs.
The cardiac differentiation protocol crucially depends on the quality of hPSCs, which in turn relies on the quality of matrix and medium, and the methods used to passage and maintain the hPSCs. We recommend mTeSR1 medium in conjunction with hPSC-qualified lots of Matrigel or the chemically defined surface Synthemax for hPSC expansion and maintenance in the undifferentiated state. An enzyme-free method of passaging the cells using Versene is recommended. The hPSCs cultivated in this manner should have a uniform undifferentiated morphology (Fig. 1a) . Undifferentiated hPSCs should express Oct4, Nanog, SSEA-4, and TRA-1-80 (Fig. 1b) . The pluripotency marker Oct4 should be expressed in greater than 95% of the cells, as assessed by flow cytometry (Fig. 1c) . Flow cytometry of Oct4 expression should be performed every three passages to validate the lack of differentiation of hPSCs. Partially differentiated hPSCs will diminish the cardiomyocyte differentiation efficiency in the protocols presented here.
Induction of mesendoderm, cardiac mesoderm and cardiomyocytes. The hPSCs are initially cultured on Matrigel-coated plates or Synthemax plates in mTeSR1 medium until they are fully confluent. Differentiation is initiated by removing the mTeSR1 medium and adding RPMI/B-27 medium lacking insulin and containing a GSK3 inhibitor, such as CHIR99021. Twenty-four hours of culture in (Fig. 2a) . To direct these brachyury-expressing mesendoderm progenitor cells to a cardiac fate, inhibition of canonical Wnt signaling either by β-catenin shRNA expression or Wnt signaling inhibitors, such as the porcupine inhibitors IWP2 or IWP4, is performed. Cardiac mesoderm cells spontaneously develop into functional contracting cardiomyocytes when cultured in RPMI/B-27 medium.
Characterization of human cardiomyocyte differentiation.
Cardiac differentiation using either the growth factor-or the small molecule-based differentiation protocols proceeds rapidly. A relatively pure ( >95%) population of brachyury-expressing mesendoderm cells can be detected after 1 d of differentiation. Gene expression of the cardiac transcription factors NKX2-5 (ref. 19) and ISL1 (refs. 20 and 21) begins at day 4, with the protein detectable at day 5 (Fig. 2b) . Cardiac troponin T (cTnT) can be readily detected at day 8 of differentiation. The presence of cardiomyocytes can be easily established by visual observation of spontaneously contracting regions. The first beating cluster of cells can be observed between days 8 and day 10, depending on the individual cell line used. Robust spontaneous contraction occurs by day 12. Cardiac marker protein expression after onset of contractions can also be assessed by immunostaining or be quantified with flow cytometry. Here we provide procedures for performing these characterizations, including optimized immunostaining and flow cytometry methods, antibody sources, antibody dilutions and a combination of antibodies that facilitate dual staining. REAGENT SETUP 293TN medium In a sterile environment, mix 50 ml of FBS, 5 ml of sodium pyruvate, 2.5 ml of GlutaMAX and 450 ml of DMEM. Filter the medium with a 500-ml Stericup filtration system. The medium can be stored at 4 °C for up to 2 months.
FBS-DMEM medium, 10% (vol/vol)
In a sterile environment, mix 50 ml of FBS and 450 ml of DMEM. Filter the medium with a 500-ml Stericup filtration system. The medium can be stored at 4 °C for up to 2 months. Formaldehyde, 1% (vol/vol) Add 62.5 µl of 16% (vol/vol) formaldehyde into 1 ml of PBS. We do not recommend storing this solution. Formaldehyde, 4% (vol/vol) Add 1 ml of 16% (vol/vol) formaldehyde into 3 ml of PBS. We do not recommend storing this solution. Methanol, 90% (vol/vol) Add 5 ml of Milli-Q water to 45 ml of pure methanol and store the solution at − 20 °C for up to 2 years. BSA, 0.1% (wt/vol) Add 1 g of BSA to 1,000 ml of PBS and filter it using a Stericup filtration system. Store the solution at 4 °C for up to 6 months. BrdU, 20 mM Add 16.28 ml of DMSO to 100 mg of BrdU to obtain a final BrdU concentration of 20 mM. Aliquot and store it at − 20 °C for up to 1 year. CHIR99021 (36 mM) Add 1.49 ml of DMSO to 25 mg of CHIR99021. Aliquot and store it at − 20 °C for up to 1 year. Doxycycline (1 mg ml − 1 ) Add 10 ml of Milli-Q water to 10 mg of doxycycline. Divide the solution into 100-µl aliquots and store them at − 20 °C for up to 1 year. hESC medium (500 ml) In a sterile environment, mix 392.5 ml of DMEM/ F12, 100 ml of KnockOut serum replacement, 5 ml of MEM non-essential
amino acids, 2.5 ml of 200 mM l-glutamine and 3.5 µl of 14.3 M β-mercaptoethanol (final concentration of 0.1 mM). The medium can be stored at 4 °C for up to 2 weeks. Freezing medium (50 ml) In a sterile environment, mix 30 ml of hESC medium, 15 ml of FBS, 5 ml of DMSO and 50 µl of Y27632. The medium can be stored at 4 °C for up to 1 month. RPMI/B-27 without insulin (510 ml) In a sterile environment, mix 500 ml of RPMI and 10 ml of B-27 without insulin. The medium can be stored at 4 °C for up to 1 month. RPMI/B-27 without insulin + 12 mM CHIR99021 (24 ml) Add 8 µl of 36 mM CHIR99021 into 24 ml of RPMI/B-27 without insulin. We do not recommend storing this medium. RPMI/B-27 (510 ml) In a sterile environment, mix 500 ml of RPMI and 10 ml of B-27 supplement. The medium can be stored at 4 °C for up to 1 month. RPMI20 (250 ml) In a sterile environment, mix 200 ml of RPMI and 50 ml of FBS; next, filter the solution through a 250-ml Stericup filtration system. The medium can be stored at 4 °C for up to 1 month. IWP2 (5 mM) Add 4.28 ml of DMSO to 10 mg of IWP2. Incubate the mixture at 37 °C for 10 min to dissolve the IWP2. Divide the solution into 100-µl aliquots in 1.5-ml tubes and store them at − 20 °C for up to 1 year. IWP4 (5 mM) Add 0.805 ml of DMSO to 2 mg of IWP4. Incubate the mixture at 37 °C for 10 min to dissolve the IWP4. Divide the solution into 100-µl aliquots in 1.5-ml tubes and store them at − 20 °C for up to 1 year. mTeSR1 + 1 mg ml − 1 puromycin Add 5 µl of 10 mg ml − 1 puromycin to 50 ml of mTeSR1 medium. The medium can be stored at 4 °C for up to 2 weeks. mTeSR1 + 1 mM CHIR99021 (24 ml) Add 0.67 µl of 36 mM CHIR99021 to 24 ml of mTeSR1 medium. The medium can be stored at 4 °C for up to 2 weeks. Y27632, 5 mM In a sterile environment, add 6.24 ml of PBS to 10 mg of Y27632. Divide the solution into 100-µl aliquots in 1.5-ml tubes and store them at − 20 °C for up to 1 year. mTeSR1 + 5 mM Y27632 Add 50 µl of 5 mM Y27632 to 50 ml of mTeSR1 (the final concentration of Y27632 is 5 µM). Store the solution at 4 °C for up to 2 weeks. Gelatin (1,000 ml), 0.1% (wt/vol) Add 1 g of gelatin to 1,000 ml of Milli-Q water and autoclave the solution at 121 °C, 15 p.s.i. for 30 min. The solution can be stored at room temperature (20-25 °C) for up to 1 year. FlowBuffer-1 (500 ml) Add 2.5 g of BSA to 500 ml of PBS and filter using a 500-ml Stericup filtration system. The medium can be stored at 4 °C for up to 6 months. Triton X-100 solution (500 ml), 1% (vol/vol) Add 5 ml of Triton X-100 to 495 ml of PBS and shake the bottle to dissolve the Triton. The medium can be stored at 4 °C for up to 6 months. FlowBuffer-2 (550 ml) Add 2.5 g of BSA and 50 ml of 1% (vol/vol) Triton X-100 solution into 500 ml of PBS and filter it using a 500-ml Stericup filtration system. The medium can be stored at 4 °C for up to 6 months. Triton X-100 solution (50 ml), 10% (vol/vol) Add 5 ml of Triton X-100 into 45 ml of PBS and shake the tube to dissolve the Triton. The medium can be stored at 4 °C for up to 6 months. Triton solution (15 ml), 2 N HCl/1% (vol/vol) Add 2.5 ml of 12 N HCl and 1.5 ml of 10% (vol/vol) Triton X-100 solution into 11 ml of Milli-Q water. We do not recommend storing this solution. Nonfat dry milk, 0.4% Triton X-100, 5% (wt/vol) Add 0.5 g of nonfat dry milk and 4 ml of 1% (vol/vol) Triton X-100 solution to 6 ml of PBS. We do not recommend storing this solution. Activin A (50 mg ml − 1 ) Dissolve 50 µg of activin A in 1 ml of 0.1% (wt/vol) BSA solution. Store it at − 80 °C for up to 6 months. BMP4 (10 mg ml − 1 ) Dissolve 10 µg of BMP4 in 1 ml of 0.1% (wt/vol) BSA solution. Store it at − 80 °C for up to 6 months. bFGF (10 mg ml − 1 ) Dissolve 10 µg of bFGF in 1 ml of 0.1% (wt/vol) BSA solution. Store the solution at − 80 °C for up to 6 months. GiAB d0 medium (12 ml) Add 24 µl of 50 µg ml − 1 activin A, 12 µl of 10 µg ml − 1 bFGF and 120 µl of KnockOut serum replacement into 12 ml of RPMI/B-27 without insulin. We do not recommend storing this medium. RPMI/B-27 without insulin + 5 ng ml − 1 BMP4 (24 ml) Add 12 µl of 10 µg ml − 1 BMP4 into 24 ml of RPMI/B-27 without insulin. We do not recommend storing this medium. 2| Remove a frozen cell vial of hPSCs, such as 19-9-11 iPSCs (WISC Bank), from liquid N 2 and immerse the vial in a 37 °C water bath without submerging the cap. Swirl the vial gently for 2-3 min until the contents are completely thawed.
3| Spray the vial with 70% (vol/vol) ethanol and place it in a tissue culture hood. Use a sterile 1-ml pipette to gently transfer the cells into a sterile 15-ml conical tube containing 5 ml of room temperature mTeSR1 medium.
4|
Centrifuge the cells at 200g for 5 min at room temperature. Aspirate and discard the supernatant with a sterilized Pasteur pipette. Aspirate the liquid from the wells of the Matrigel-coated plate.
5|
Resuspend the cell pellet in 6 ml of mTeSR1 medium + 5 µM Y27632. Slowly add 2 ml of the cell suspension into each well of the Synthemax or Matrigel-coated six-well plate (one vial to three wells). Put the plate back into the 37 °C, 5% CO 2 incubator. Move the plate in three quick, short, back-and-forth and side-to-side motions to disperse the cells across the surface of the wells.  crItIcal step Including a ROCK inhibitor is very important for high hPSC recovery after freezing and thawing. We recommend preparing freezing medium as follows: 10% DMSO, 30% FBS, 60% hESC medium by volume, supplemented with 5 µM Y27632. We also recommend using 5 µM Y27632 in the medium when culturing hPSCs for the first 24 h after thawing.
6|
On the next day, aspirate the medium in each well and replace it with 2 ml of fresh room temperature mTeSR1 medium. Repeat this medium replacement daily until cells are ready for passage (Step 7). ? trouBlesHootInG passaging hpscs using Versene • tIMInG 10 min (plus 4 d for maintenance) 7| When the cells are 80-90% confluent (usually about 3-5 d after passaging, daily monitoring is necessary), aspirate the old medium and then add 1 ml of room temperature Versene to each well. At this point, 1-1.5 million cells should be present in each well.
8|
Incubate the plate at 37 °C, 5% CO 2 and wait for 4 min.
9|
Aspirate the Versene and then hold a 5-ml pipette filled with 3 ml of mTeSR1 + 5 µM Y27632 perpendicular to the plate and dispense the medium over the surface of the plate well until all the cells are detached. After the cells are removed from the surface of the well, pool the contents of the well into a sterile conical tube containing 9 ml of mTeSR1 + 5 µM Y27632 and gently mix the tube contents 5-10 times using a 5-ml pipette. Seed 2 ml of the cell suspension into each well of a Matrigel-coated or Synthemax six-well plate (a split ratio of 1:6 is performed here).  crItIcal step The split ratio is variable, although generally between 1:6 and 1:18 is appropriate when using Versene for passaging. A general rule is to observe the last split ratio and adjust the ratio according to the appearance of the hPSC colonies. If the cells have an undifferentiated morphology (colony diameter <500 µm) and colonies have enough space (more than 10 µm) between them to expand, split them using the same ratio. If they are overly dense and crowded (colony diameter >500 µm, spacing between colonies <10 µm), increase the ratio; decrease the ratio if the cells are sparse (colony diameter <50 µm, spacing between colonies >500 µm).
10|
Return the plate to the incubator after plating the cells. Move the plate in three quick, short, back-and-forth and sideto-side motions to disperse the cells across the surface of the wells.
11|
On the next day, aspirate the medium and add 2 ml of fresh room temperature mTeSR1 per well. Repeat this medium replacement daily until cells are 80-90% confluent (usually about 3-5 d after passaging); daily monitoring is necessary. Pluripotent cell culture can be maintained by repeating Steps 7-11 before moving to the next step for cardiac differentiation. We have been able to generate highly efficient cardiomyocytes ( > 80% cTnT + ) from hPSCs with passages ranging from passage 20 to passage 90.
cardiac differentiation of hpscs 12| Perform cardiac differentiation by treatment of hPSCs with small-molecule modulators of Wnt signaling and TGFβ superfamily growth factors. Small-molecule methods (options A and B) rely on a common initial treatment of hPSCs with the GSK3 inhibitor, followed by doxycycline-inducible expression of β-catenin shRNA (option A) or IWP treatment (option B). Option A (GiSB) requires genetic modification of hPSCs to inducibly express β-catenin shRNA. For option B (GiWi), we use small-molecule inhibitors of Wnt signaling (IWPs) instead of β-catenin shRNA in the GiWi protocol (option B); genetic modification of hPSCs to inducibly express β-catenin shRNA is not required for this protocol. The GiWi protocol is applicable to any existing hPSC line. A summary of the option B procedure is shown in Figure 3 . Scientists may also be interested in comparing the small molecule-derived cardiomyocytes with cardiomyocytes differentiated from hPSCs using growth factors of TGFβ superfamily. The approach for generating cardiomyocytes via our GSK3 inhibitor/activin A/BMP4 method is provided in option C (GiAB). , aspirate the medium from each well. Add 1 ml of room temperature mTeSR1 + 5 µM Y27632 + 1 ml virus supernatant (pXL002 or pXL004) per well of a six-well plate and incubate the mixture for 24 h. (vi) Aspirate and discard the medium (day 2), and then add 2 ml of room temperature mTeSR1 per well. Incubate the cells for a further 24 h. (vii) Aspirate and discard the medium (day 3) and add 2 ml of room temperature mTeSR1 + 1 µg ml − 1 puromycin to kill the nontransduced cells. Incubate the mixture for 24 h (day 4) and repeat the medium replacement with mTeSR1 + 1 µg ml − 1 puromycin. (viii) After an additional 24-h incubation (day 5), aspirate the medium and then add 1 ml of Accutase into the transduced well and incubate the cells at 37 °C, 5% CO 2 for 10 min. Add 1 ml of mTeSR1 into the transduced well and pool the cells in a 15-ml tube. You will have a total of 2 ml of cell mixture per virus-transduced sample. Count 10 µl of each cell mixture using a hemocytometer. (ix) Centrifuge the cells at 200g for 5 min at room temperature and aspirate the supernatant. Perform the required number of serial dilutions to obtain ~1 cell per 100 µl. Assuming x million cells in total, first resuspend the cells in 10 times x ml of mTeSR1 to obtain a cell density of 10 5 cells per ml. Add 100 µl of the mixture into another new 10 ml of mTeSR1 to obtain a cell density of 10 3 cells per ml. Next, add 100 µl of the 10 3 cells per ml mixture into another 10 ml of mTeSR1 + 5 µM Y27632 to obtain a cell density of 10 1 cells per ml (1 cell per 100 µl). (x) Add 100 µl of the 10 1 cells per ml suspension from Step 12A(ix) into each well of a 96-well plate precoated with Matrigel. Under the microscope, check and mark the wells that contain only a single cell. Only the wells that contain exactly one cell should be subjected to further analysis. Approximately ~50 wells will contain exactly one cell. (xi) Place the 96-well plate in a 37 °C, 5% CO 2 incubator for 4 d without changing the medium. (xii) Four days after plating, aspirate the medium and add 100 µl of mTeSR1 + 5 µM Y27632 + 1 µg ml − 1 puromycin.
Continue to incubate the cells and repeat this medium change every other day until 12 d after plating. as described in Steps 7-11. At the desired time, knockdown efficiency can be assessed as described in Step 12A(xvii-xix). (xvii) To identify the best inducible knockdown clones before cardiomyocyte differentiation via the GiSB protocol, aspirate the old medium and add 2 ml of mTeSR1 + 4 µl of 1 mg ml − 1 doxycycline into the well of a six-well plate daily for 3 d. (xviii) Aspirate the medium, add 1 ml of Accutase and incubate at 37 °C, 5% CO 2 for 10 min. Add 1 ml of mTeSR1 into the well and pool all of the cells in a 15-ml tube. Centrifuge the cells at 200g for 5 min at room temperature. (xix) Aspirate the supernatant and extract the RNA using the Qiagen RNeasy mini kit according to the manufacturer's instructions. Next, generate cDNA from the mRNA with the Omniscript RT kit according to the manufacturer's instructions. Perform quantitative PCR with the QuantiTect SYBR Green PCR kit according to the manufacturer's recommendations using the RT-PCR GAPDH and CTNNB1 primers (see Reagents). The knockdown efficiency of β-catenin can be measured by quantitative PCR comparing the expression in the inducible knockdown cells to nontransduced cells and inducible scramble shRNA-transduced cells. The best knockdown efficiency clone should be expanded for further cardiac differentiation. Clones that show at least 80% knockdown efficiency of β-catenin are sufficient for robust cardiac differentiation using Step 12A(xx-xxviii) below. (xx) Cardiac differentiation with the GSK3 inhibitor and inducible shRNA of β-catenin (GiSB protocol). Take the chosen inducible β-catenin shRNA clone cells grown on Matrigel-coated or Synthemax six-well plates in mTeSR1 medium to 80-90% confluence (from Step 12A(xvi)). Aspirate the medium and add 1 ml of room-temperature Accutase to each well. Put the plate in a 37 °C, 5% CO 2 incubator and wait for 8 min. Add mTeSR1 + 5 µM Y27632 medium to each well to obtain a final volume of 1 ml in each well of the 12-well plate. Incubate the cells. This time point corresponds to day − 4 of differentiation.  crItIcal step The starting seeding cell density is crucial for efficient cardiac differentiation. The initial plating density and/or the time of expansion before initiation of differentiation may require optimization for different cell lines or expansion conditions. We recommend plating at a cell density of 0.5 million cells per well of 12-well plate and increasing this stepwise to 1.5 million for your specific hPSC lines in your first experiment, and then expanding the cells for 4 d before initiation of differentiation. Once you have identified the optimal seeding density for your specific hPSC lines, you can use this seeding density for subsequent differentiation experiments. (xxiii) On day − 3, day − 2 and day − 1 of differentiation, aspirate the medium and replace it with 2 ml of room temperature mTeSR1 per well of the 12-well plate. (xxiv) On day 0 of differentiation, prepare 12 µM CHIR99021 RPMI/B-27 without insulin. You will need 2 ml of RPMI/B-27 without insulin for each well of the 12-well plate, and thus 24 ml to differentiate cells in all 12 wells. Add 8 µl of 36 mM CHIR99021 into 24 ml of RPMI/B-27 without insulin medium to make 12 µM CHIR99021 RPMI/B-27 without insulin medium. Aspirate the old medium and then add 2 ml of RPMI/B-27 without insulin with CHIR99021 to each well of the 12-well plate and record the time.  crItIcal step Recording the time when you added RPMI/B-27 without insulin with CHIR99021 is important, as exactly 24 h later you need to change the medium. Although we identified 12 µM CHIR99021 as the optimal concentration for the six lines that we tested, other lines may respond to CHIR99021 treatment differently. Thus, optimization of CHIR99021 concentration may be required. We recommend testing 6-14 µM CHIR99021.
? trouBlesHootInG (xxv) After 24 h (day 1 of differentiation), aspirate the medium from each well of the 12-well plate and replace it with 2 ml of room-temperature RPMI/B-27 without insulin. Put the plate back into the 37 °C, 5% CO 2 incubator.
Box 1 | Inducible b-catenin shRNA lentivirus production 1 . Expand both of the plasmids (pXL002 and pXL004; pXL002 is for production of inducible β-catenin shRNA and pXL004 is for production of inducible scrambled shRNA as a negative control) used for lentiviral production in Stbl3 E. coli and extract the plasmids with the Qiagen EndoFree Plasmid maxi kit or PureLink HiPure plasmid midiprep kit according to the manufacturer's recommendations 23 .
Resuspend the plasmid in elution buffer (part of the kit) at a concentration of ~1 µg µl − 1 .  crItIcal step Inducible β-catenin shRNA lentivirus can be produced while Steps 1-6 or 7-11 of the main PROCEDURE are being performed.
2. Thaw a vial of 293TN cells quickly by incubating it in a 37 °C water bath. Transfer the contents into a 15-ml conical tube containing 9 ml of 293TN medium. Centrifuge the cells at 200g for 5 min at room temperature. Discard the supernatant. Resuspend 0.5 million cells per ml in 6 ml of 293TN medium and transfer them evenly into three wells of a six-well plate (1 million cells per well).
Incubate the plates at 37 °C, 5% CO 2 for 24-48 h or until the cells reach 95-100% confluence.  crItIcal step It is recommended to initially prepare several frozen aliquots of 293TN cells for subsequent lentivirus production. 3. Add 4.5 µg of pXL002 (or pXL004), 3.0 µg of psPAX2 and 1.5 µg of pMD2.G to 450 µl of Opti-MEM medium and incubate the mixture at room temperature for 5 min. Add 27 µl of FuGENE HD reagent. Mix carefully by pipetting 15 times with a P200 tip. Incubate the mixture for 10-15 min at room temperature. Add 450 µl of the plasmid mixture into 3 ml of 293TN medium prewarmed to 37 °C. Aspirate the old medium from the six-well plate with 293TN cells and add 1 ml of 293TN medium containing FuGENE/DNA complex to each well of the six-well plate. Incubate the mixture at 37 °C, 5% CO 2 .  crItIcal step Add the medium gently along the wall of the six-well plate to 293TN cells, as 293TN cells adhere weakly and directly mechanical disturbance or contact with medium can cause their detachment. The addition of medium along the wall will help the 293TN cells remained attached.
? trouBlesHootInG 4. At 16-18 h after the addition of the plasmid mixture to the 293TN cells, aspirate the medium from each well and replace it with 3 ml per well of 293TN medium prewarmed to 37 °C. Incubate the plate at 37 °C, 5% CO 2 for 24 h. 5. Use a 5-ml pipette to collect the virus-containing supernatant; transfer the supernatant to a 50-ml conical tube and store it at 4 °C. Add 3 ml of 293TN medium prewarmed to 37 °C to each well of the six-well plate and incubate the cells. 6. Repeat step 5 after 24 and 48 h. In total, you will obtain about 27 ml of virus-containing supernatant. Immediately after collection, chill the virus-containing supernatant on ice and store it at 4 °C. 7. Centrifuge the virus-containing medium at 2,000g at 4 °C for 5 min to pellet cell debris, and then filter the supernatant through a 0.45-µm filter. 8. Aliquot the lentiviral supernatant into microcentrifuge tubes at a volume of 1 ml per tube and store them at − 80 °C for up to 1 year.  pause poInt The lentiviral supernatant can be stored in a − 80 °C freezer for up to 1 year.
(xxvi) After 12 h (i.e., exactly 36 h after addition of CHIR99021), add 4 µl of 1 mg ml − 1 doxycycline per well of a 12-well plate with a P10 tip and pipette to mix. Put the plate back into the 37 °C, 5% CO 2 incubator.  crItIcal step Cardiomyocyte differentiation is very sensitive to the timing of Wnt pathway modulation. During small-molecule-directed differentiation, optimization of timing of Wnt pathway regulators can generate up to 98% cTnT + cardiomyocytes. To achieve a high purity of cardiomyocytes by β-catenin knockdown, doxycycline addition must be initiated within 1-2 h of the 36-h postdifferentiation optimum.  crItIcal step Do not change the medium between day 1 and day 5. (xxvii) On day 5 of differentiation, aspirate the medium from each well of the 12-well plate and add room-temperature RPMI/B-27 without insulin at a volume of 2 ml per well. Put the plate back into the 37 °C, 5% CO 2 incubator. (xxviii) On day 7 of differentiation and every 3 d thereafter, aspirate the medium from each well and add room-temperature RPMI/B-27 medium at a volume of 2 ml per well. Put the plate back into the 37 °C, 5% CO 2 incubator. Robust spontaneous contraction should occur by day 12. Two typical spontaneously contracting results from the 19-9-11-inducible β-catenin shRNA line are shown in supplementary Video 1 (day 15 cardiomyocytes) and supplementary Video 2 (day 180 cardiomyocytes).
? trouBlesHootInG (B) cardiac differentiation with the GsK3 inhibitor and Wnt inhibitor (GiWi protocol) • tIMInG 14 d
(i) Take hPSCs cultured on Matrigel-coated or Synthemax six-well plates in mTeSR1 medium at 80-90% confluence. Follow
Step 12A(xx-xxv). Rather than performing Step 12A(xxvi), proceed as detailed below.  crItIcal step This GiWi protocol does not require transgenic modification of hPSCs to inducibly express β-catenin shRNA. Existing hPSCs can be used directly with the GiWi protocol to produce cardiomyocytes. (ii) On day 3 of differentiation (72 h after addition of CHIR99021), prepare combined medium by using a 5-ml pipette to collect 1 ml of medium from the 12-well plate; mix it with 1 ml of fresh RPMI/B-27 without insulin medium in a 15-ml conical tube. Add 2 µl of 5 mM IWP2 (final concentration is 5 µM) into the 2 ml of combined medium. Before aspirating 1 ml of the remaining medium in the well of the 12-well plate, gently rock the plate back and forth to get cell debris into suspension, ensuring that the cell debris will be discarded via aspiration. Aspirate the remaining 1 ml of medium from each well of the 12-well plate, and then add 2 ml per well of the combined medium containing IWP2 to each well and incubate the cells. (iii) On day 5 of differentiation, aspirate the medium from each well of the 12-well plate and add room-temperature RPMI/B-27 without insulin at a volume of 2 ml per well. Put the plate back into the 37 °C, 5% CO 2 incubator. (iv) On day 7 of differentiation and every 3 d thereafter, Aspirate the medium from each well of the 12-well plate and add room-temperature RPMI/B-27 medium at a volume of 2 ml per well. Put the plate back into the 37 °C, 5% CO 2 incubator. Robust spontaneous contraction should occur by day 12. The cells can be maintained with this spontaneously beating phenotype for more than 6 months. ? trouBlesHootInG (c) Directed differentiation with GsK3 inhibitor, activin a and BMp4 (GiaB protocol) • tIMInG 14 d (i) Take hPSCs cultured on Matrigel-coated or Synthemax six-well plates in mTeSR1 medium that are 80-90% confluent; aspirate the medium and add 1 ml of room-temperature Accutase to each well. Put the plate back into the 37 °C, 5% CO 2 incubator and wait for 8 min.  crItIcal step The starting seeding cell density is crucial for efficient cardiac differentiation. The initial plating density and/or the time of expansion before initiation of differentiation may require optimization for different cell lines or expansion conditions. We recommend plating at a cell density of 0.5 million cells per well of 12-well plate and increasing this stepwise to 1.5 million for your specific hPSC lines in your first experiment, and then expanding the cells for 4 d before initiation of differentiation. Once you have identified the optimal seeding density for your specific hPSC lines, you can use this seeding density for subsequent differentiation experiments. (iv) On day − 3, day − 2 and day − 1 of differentiation, aspirate the medium and replace it with 2 ml of mTeSR1 + 1 µM CHIR99021 per well of a 12-well plate. (v) On day 0 of differentiation, add 100 ng ml − 1 activin A, 10 ng ml − 1 bFGF and 1% (vol/vol) KnockOut serum replacement into RPMI/B-27 without insulin. This medium is named GiAB d0 medium. Aspirate the old medium and then add 1 ml of GiAB d0 medium per well to the 12-well plate and record the time.  crItIcal step Recording the time when you finished adding GiAB d0 medium is important, as exactly 24 h later you need to change the medium.
(vi) Exactly 24 h after the medium change, aspirate the medium from each well and replace it with 2 ml of room-temperature RPMI/B-27 without insulin + 5 ng ml − 1 BMP4 + 5 ng ml − 1 bFGF. Put the plate back into the 37 °C, 5% CO 2 incubator.  crItIcal step The BMP4 concentration on day 1 of differentiation for optimal cardiac differentiation using the GiAB protocol varies with different cell lines. Optimization of the BMP4 concentration (we recommend testing from 0 to 10 ng ml − 1 ) may be required to achieve efficient cardiomyocyte differentiation. Do not change the medium between day 1 and day 5. (vii) On day 5 of differentiation, aspirate the medium from each well and add room-temperature RPMI/B-27 without insulin at a volume of 2 ml per well. Put the plate back into the 37 °C, 5% CO 2 incubator. (viii) On day 7 of differentiation and every 3 d thereafter, aspirate the medium from each well and add room-temperature RPMI/B-27 medium at a volume of 2 ml per well. Put the plate back into the 37 °C, 5% CO 2 incubator. Robust spontaneous contraction should occur by day 12.
? trouBlesHootInG characterization of hpsc-derived cardiomyocytes 13| At 14 d after differentiation, the cells should show hallmarks of cardiomyocytes, including spontaneous contraction and cardiac-specific gene and protein expression. To characterize cells, perform sarcomere immunostaining (option A) and flow cytometry analysis (option B). In addition, perform BrdU and MF20 flow cytometry analysis (option C). The protocol for analysis of BrdU and MF20 (option C) is different from other combinations of antibodies. We recommend flow cytometry for quantitative analysis of the purity of hPSC-derived cardiomyocytes. Antibody combinations of cTnT/SMA, cTnT/MLC2a and MF20/Ki67 are recommended for double staining. (a,b) Cardiomyocytes were generated from 6-9-9 ishcat-1 iPSCs using the protocol described in Step 12A, with 12 µM CHIR99021 treatment at day 0 and 2 µg ml − 1 doxycycline treatment at day 1.5. At day 30, cells were individualized and replated on 0.1% gelatin-coated coverslips.
Immunostaining for α-actinin (green) and MLC2a (red) shows sarcomere organization. Nuclei were stained with DAPI (blue). Repeat this step once to remove the sodium tetraborate. (viii) Follow Step 13B(vi-viii) using MF20 and BrdU antibodies at concentrations indicated in table 2. A typical result from BrdU and MF20 flow cytometry analysis is shown in Figure 5 .
? trouBlesHootInG Troubleshooting advice can be found in table 3. antIcIpateD results This protocol presents a rapid and efficient (80-98% cTnT + cells after 2 weeks) method for the generation of functional cardiomyocytes from multiple hPSC lines. Before starting the differentiation protocol, well-maintained hPSCs should have a high nucleus-to-cytoplasm ratio, prominent nucleoli morphology (Fig. 1a) and be uniformly positive for pluripotency markers, including Oct4, Nanog, TRA-1-80 and SSEA-4 (Fig. 1b,c) . At 24 h after initiation of differentiation with CHIR99021, at least 90% of the total differentiated cells should express brachyury, the mesendoderm marker (Fig. 2a) . Mesendoderm differentiation below 90% could be caused by the poor quality of the starting hPSCs. After 5-6 d of differentiation, cells will express the cardiac progenitor marker protein Isl1 (Fig. 2b) . The first beating cluster of cells can be observed between day 8 and day 10, depending on the individual cell line used. Robust spontaneous contraction occurs by day 12 in all hPSCs that we tested. Cardiac sarcomere proteins, such as α-actinin, MLC2a and cTnT, will be expressed in more than 80% of the differentiated cells (Figs. 3-5 ) by day 15. About 20% of the day 20 cardiomyocytes should show proliferative capacity via Ki67 or BrdU incorporation analysis (Fig. 5b) . We typically generate ~3-5 million cardiomyocytes (80-98% cTnT + ) (table 1) per well of a 12-well plate (surface area = 3.8 cm 2 ), resulting in a total density of day 15 cardiomyocytes equal to 0.8-1.3 million cardiomyocytes per cm 2 . Initial cell seeding density is not optimal or day 1 BMP4 concentration is not optimal; efficient brachyury or Nkx2.5 expression is not induced
Optimize initial cell seeding density; optimize BMP4 (0-10 ng ml − 1 ) for your specific lines
